Sri Vidya Ramisetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sri Vidya Ramisetti has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Akhileshwar Namani
Department of Molecular Oncology, Sri Shankara Cancer Hospital and Research Centre, Sri Shankara National Centre for Cancer Prevention and Research, Sri Shankara Cancer Foundation, Bangalore, India
1 shared publication
Latest Publications
- Open Access
- 16 March 2023
- Published by MDPI AG in Medical Sciences Forum
- Vol. 20 (1) , 1
Multi-Omics Analysis of NFE2L2-Altered TCGA-Cervical Squamous Cell Carcinoma Patients
Genetic alterations in the NFE2L2 gene have been identified across various cancers, and the dysregulation of the NRF2 pathway due to these alterations leads to drug and radioresistance in several cancers. Identification of biomarkers associated with these alterations allows researchers and clinicians to provide personalized medicine and a quicker diagnosis. In this current study, we carried out an integrated, multi-omics, multi-database analysis of exome and transcriptomic data of NFE2L2-altered TCGA-Cervical squamous cell carcinoma (CSCC) patients against wild-type counterparts. Finally, we discovered the genes associated with NFE2L2 alterations and identified the prognostic genes which could be used as potential biomarkers in the NFE2L2-mutated CSCC patients. Our findings might be useful in the early diagnosis of NFE2L2-mutated CSCC patients.
- 16 March 2023
- Published by MDPI AG in Medical Sciences Forum
- Vol. 20 (1) , 1
Open AccessMulti-Omics Analysis of NFE2L2-Altered TCGA-Cervical Squamous Cell Carcinoma Patients
Genetic alterations in the NFE2L2 gene have been identified across various cancers, and the dysregulation of the NRF2 pathway due to these alterations leads to drug and radioresistance in several cancers. Identification of biomarkers associated with these alterations allows researchers and clinicians to provide personalized medicine and a quicker diagnosis. In this current study, we carried out an integrated, multi-omics, multi-database analysis of exome and transcriptomic data of NFE2L2-altered TCGA-Cervical squamous cell carcinoma (CSCC) patients against wild-type counterparts. Finally, we discovered the genes associated with NFE2L2 alterations and identified the prognostic genes which could be used as potential biomarkers in the NFE2L2-mutated CSCC patients. Our findings might be useful in the early diagnosis of NFE2L2-mutated CSCC patients.